Applications of metabolomics and proteomics to the mdx mouse model of Duchenne muscular dystrophy: lessons from downstream of the transcriptome by Griffin, Julian L & Des Rosiers, Christine
Genome Medicine 2009, 1 1: :32
Review
A Ap pp pl li ic ca at ti io on ns s   o of f   m me et ta ab bo ol lo om mi ic cs s   a an nd d   p pr ro ot te eo om mi ic cs s   t to o   t th he e   m md dx x m mo ou us se e   m mo od de el l   o of f
D Du uc ch he en nn ne e   m mu us sc cu ul la ar r   d dy ys st tr ro op ph hy y: :   l le es ss so on ns s   f fr ro om m   d do ow wn ns st tr re ea am m   o of f   t th he e
t tr ra an ns sc cr ri ip pt to om me e
Julian L Griffin* and Christine Des Rosiers†
Addresses: *Department of Biochemistry, Tennis Court Road, University of Cambridge, Cambridge, CB2 1QW, UK. †Department of Nutrition
and Montreal Heart Institute, Université de Montréal, Montreal, Quebec H3C 3J7, Canada.
Correspondence: Julian L Griffin. Email: jlg40@cam.ac.uk 
A Ab bs st tr ra ac ct t
Functional genomic studies are dominated by transcriptomic approaches, in part reflecting the
vast amount of information that can be obtained, the ability to amplify mRNA and the availability
of commercially standardized functional genomic DNA microarrays and related techniques. This
can be contrasted with proteomics, metabolomics and metabolic flux analysis (fluxomics), which
have all been much slower in development, despite these techniques each providing a unique
viewpoint of what is happening in the overall biological system. Here, we give an overview of
developments in these fields ‘downstream’ of the transcriptome by considering the characteri-
zation of one particular, but widely used, mouse model of human disease. The mdx mouse is a
model of Duchenne muscular dystrophy (DMD) and has been widely used to understand the
progressive skeletal muscle wasting that accompanies DMD, and more recently the associated
cardiomyopathy, as well as to unravel the roles of the other isoforms of dystrophin, such as those
found in the brain. Studies using proteomics, metabolomics and fluxomics have characterized
perturbations in calcium homeostasis in dystrophic skeletal muscle, provided an understanding of
the role of dystrophin in skeletal muscle regeneration, and defined the changes in substrate
energy metabolism in the working heart. More importantly, they all point to perturbations in
proteins, metabolites and metabolic fluxes reflecting mitochondrial energetic alterations, even in
the early stage of the dystrophic pathology. Philosophically, these studies also illustrate an
important lesson relevant to both functional genomics and the mouse phenotyping in that the
knowledge generated has advanced our understanding of cell biology and physiological
organization as much as it has advanced our understanding of the disease.
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I In nt tr ro od du uc ct ti io on n
The completion of genome projects, such as those associated
with the mouse [1] and humans [2], heralded the field of
functional genomics, in which high-throughput approaches
are used to profile a tier of organization in a cell, tissue or
even organism after perturbation of a gene’s function in
order to deduce what the function of that gene is. By far the
commonest approach used in the armory of functional
genomic technology is probably the DNA microarray, which
is used to profile the transcriptome that results from a gene
manipulation. Although this technology has proven to be
incredibly powerful in deducing the consequences of certain
genetic modifications, there are situations in which such an
approach may not be successful. Approaches based on trans-
criptomics make the assumption that altered concentrations
of mRNA are reflected in the proteome, but this may not be
true if the concentration of a given protein is determined by
the rate of its destruction. Furthermore, although long-term
changes in the function of a cell or tissue may be caused by
changes in gene expression, in mammals many medium-term changes arise from protein modifications, such as
phosphorylation, acetylation and ubiquitylation, although
short-term changes are often caused by allosteric modifi-
cations, reflecting rapid transient changes in metabolites.
This has led to tools to profile the proteome and the metabo-
lome of a cell, tissue or organism to complement approaches
using transcriptomics.
In addition to understanding gene function, functional
genomic technologies have also been used to help in pheno-
typing organisms. One of the first applications of meta-
bolomics was in the phenotyping of yeast (Saccharomyces
cerevisiae) mutants in which genetic modifications had
produced ‘silent phenotypes’ in terms of the growth rate, the
main phenotype used to distinguish mutants [3]. Raams-
donk and colleagues [4] described an approach described as
‘functional analysis by co-responses in yeast’ (FANCY),
which distinguishes different classes of yeast mutants by
global metabolic changes [3-5]. Such a process of defining a
phenotype through the global changes induced in metabo-
lism can be used to predict the function of genes deleted or
upregulated in a given system through comparative meta-
bolomics. The definition of a metabolic phenotype, or
metabotype, by large-scale analysis of metabolites using
either  1H nuclear magnetic resonance (NMR) spectroscopy
or mass spectrometry (MS) has found many applications in
genetic engineering, toxicology and disease diagnosis in
plants, animals and microbes [6-9].
Similar to metabolomics, metabolic flux analysis using iso-
topically labeled substrates can provide novel and
unexpected insights into the metabotype of normal and
diseased cells, tissues or organisms. The use of isotopes
provides unique insights into the dynamics of cellular
metabolism and its regulation, information that is not
accessible from static measurements of mRNA or protein
expression or metabolite concentration. This subdiscipline
of metabolomics, which has been referred to as tracer-based
metabolomics, dynamic metabolomics or fluxomics and is
probably the least developed of all functional genomic
technologies, builds on stable isotope methodologies that
have been developed over the past two decades and involves
analysis of isotopomers by MS and/or NMR (for reviews see
[10-16]). In this article, we use the nomenclature followed by
most biological investigators [16], in which there are two
types of isotopomers: (i) positional isotopomers, which have
identical global isotopic composition but differ by the
position of the heavy atoms in the molecule; and (ii) mass
isotopomers, which differ by the number of heavy atoms in
their molecules, resulting in different molecular weights.
Here, we focus on the application of proteomics, metabo-
lomics and the related approach of fluxomics to understand
the function of dystrophin, the protein associated with
muscular dystrophy, through a widely used mouse model of
the disease. However, our purpose is not to focus on the
disease  per se, but to use this as a model for what the
‘downstream’ high-throughput approaches have to offer to
functional genomics and high-throughput mouse pheno-
typing and how such approaches can contribute to our
understanding of the consequences of a specific genotype
and/or therapeutic strategies.
D Du uc ch he en nn ne e   m mu us sc cu ul la ar r   d dy ys st tr ro op ph hy y   a an nd d   t th he e   m md dx x m mo ou us se e
Duchenne muscular dystrophy (DMD) is an X-linked
recessive disorder, affecting one in roughly 3,500 male
births, and is characterized by progressive muscle wasting,
culminating in death from respiratory or cardiac failure
[17,18]. The mutated gene that causes DMD was identified in
1986 [19] and is currently the longest gene known, covering
2,400 kilobases. It is composed of at least 85 exons, which
have been conserved throughout evolution, and introns
make up 98% of the gene. The dystrophin gene encodes
many different tissue-specific dystrophin isoforms generated
by use of alternative promoters and differential splicing
[20,21]. In 1987, the product of the gene was identified as
dystrophin [22]. It is a rod-shaped cytoplasmic protein con-
sisting of over 3,500 amino acids and is a central part of the
dystrophin-associated protein (DAP) complex that connects
the cytoskeleton of muscle fibers to the extracellular matrix.
Most DMD patient mutations introduce premature stop
codons that disrupt the reading frame, resulting in very little
or a complete lack of dystrophin, whereas patients with
Becker muscular dystrophy (BMD), a less severe form of
muscular dystrophy, have mutations that maintain dys-
trophin’s open reading frame, resulting in reduced expres-
sion of dystrophin or generating a truncated partially func-
tional protein [23]. Of potential broader clinical relevance,
changes in the structural integrity of dystrophin have
recently been documented in patients with end-stage
dilated, ischemic and viral cardiomyopathies and thus may
represent a common pathway for contractile dysfunction in
the failing heart [24-26].
There are several human isoforms of dystrophin proteins in
various parts of the body. In fact, there are three full-length
isoforms of dystrophin: M-dystrophin, found in muscle and,
to a small extent, glial cells in the brain; P-dystrophin, found
in the Purkinje cells of the cerebellum; and C-dystrophin,
found in the cerebral cortex [27]. Furthermore, there are
several truncated forms of dystrophin [28]. The purpose of
these isoforms, particularly those found in non-muscle
tissue and the truncated forms, are not understood [27,28].
This illustrates the difficulty with moving from the genome
to an understanding of the proteome.
T Th he e   r ro ol le e   o of f   d dy ys st tr ro op ph hi in n   i in n   t th he e   c ce el ll l
Despite the wealth of information now available on the
structure and role of dystrophin, predominantly in skeletal
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integral member of the link between the cytoskeleton and
the extracellular matrix, dystrophin is hypothesized to have
a role in stabilizing the sarcolemma (the muscle cell mem-
brane) and maintaining muscle fiber integrity during muscle
contraction [29-31]. Dystrophin may also participate in the
regulation of intracellular calcium levels [32]. There is also
evidence of increased activity of the calcium leak channel in
dystrophic muscle [33], which in turn can lead to elevated
levels of proteases in dystrophic tissue. Additional roles
hypothesized for dystrophin include a role in force and
signal transduction processes and in the aggregation of
neurotransmitter receptors. In normal muscle, neuronal
nitric oxide synthase (nNOS) associates with syntrophin in
the DAP complex. However, nNOS is absent from the
skeletal-muscle sarcolemma in DMD patients [34]. Interest-
ingly, a recent study by Acharyya et al. [35] provided evi-
dence that dystrophin itself can mediate signals relevant to
muscle atrophy and hypertrophy, possibly involving Akt
signaling. Finally, at least in the heart, dystrophin has also
been recently proposed to be an end-target of ischemic pre-
conditioning, a powerful cardioprotective intervention [36].
One of the most widely used models of this disease is the
mdx mouse, which also has a missense mutation in the gene
for dystrophin [37]. The skeletal muscle of mdx mice has a
disrupted membrane skeleton with regions of the sarco-
lemma devoid of costameres (the structures connecting the
force-generating sarcomeres with the extracellular matrix)
[38], and their cytoskeletal γ-actin has been found not to be
stably associated with the sarcolemma [39]. Although the
mdx mouse has a pronounced hunch, lower muscle re-
generative capacity and cardiomyopathic abnormalities
compared with wild-type controls [40,41], the phenotype of
the disorder is milder in the mouse than in human sufferers
unless the mouse is subjected to physical exercise [42] or to
ex vivo or in vivo increases in mechanical workload [43,44].
The mouse has only a modest decrease in life expectancy,
whereas human sufferers of DMD experience severe muscle
wasting culminating in death within the second decade.
This suggests two alternative and not mutually exclusive
hypotheses. Firstly, other proteins may compensate the
failure to express dystrophin in the mouse but not in
humans. Alternatively, it may be that the mouse in a cage is
not subject to the same stressor events as humans. It also
highlights the difficulties that remain moving from a
genomic description of a disease to an understanding of the
functional phenotype in different organisms. In terms of
species differences, one important difference in the
development of the mdx mouse compared with human DMD
sufferers is that skeletal muscle tissue in the mouse under-
goes a wave of necrosis followed by recovery at 2-3 months.
This recovery is absent in the development in humans.
Identification of the mechanisms involved in muscle
recovery may identify potential ways to treat the disorder in
humans. It also shows that tools are needed to place the
milder phenotype detected in the mouse in the biological
context of an altered proteome and metabolome.
P Pr ro ot te eo om mi ic cs s   a an nd d   t th he e   m md dx x m mo ou us se e
Given the central importance of dystrophin in maintaining
the connection between the cytoskeleton and the
extracellular matrix, a proteomic approach to understanding
the disease, perhaps investigating the changes induced in the
DAP complex, would be expected to be highly profitable.
However, when Ge and colleagues [45] examined the
changes in protein expression in the hindlimb muscles of
three-month old mdx mice using a combination of two-
dimensional gel electrophoresis and MS, the largest change
was associated with a decrease in abundance of adenylate
kinase 1, which was confirmed by biochemical assay. Doran
and colleagues [46] used a similar approach based on two-
dimensional fluorescence difference gel electrophoresis
(DIGE) to demonstrate an increase in levels of the heat-
shock protein cvHSP in the diaphragm, along with
alterations in 35 out of 2,398 detected proteins, with
decreased expression of the F-box protein Fbxo11, adenylate
kinase, β-hemoglobin and dihydrolipoamide dehydrogenase
and increased expression of cvHSP, aldehyde reductase,
desmin, vimentin, chaperonin and cardiac and muscle
myosin heavy chain.
So why have these studies highlighted alterations in
metabolism and responses to stress, rather than alterations
in the DAP complex? It is important to consider some of the
limitations of proteomic approaches based on two-dimen-
sional gels. Many low-concentration proteins can be
obscured by highly expressed proteins, which dominate the
two-dimensional gels. In particular, many of the enzymes
involved in key metabolic pathways, such as adenylate
kinase, are both readily separated on a two-dimensional gel
and found in high concentrations in the cell and thus would
be expected to be prominent in a global analysis of proteins
that separate by two-dimensional gel electrophoresis. An
alternative approach is to try a targeted analysis. To test the
hypothesis that dystrophic muscle is more susceptible to cell
death because of altered Ca2+ handling, Doran and colleagues
[47] used the cationic carbocyanine dye ‘stains-all’ to
specifically examine the Ca2+ binding proteins and demon-
strated a reduction in luminal Ca2+-binding proteins,
including calsequestrin, in skeletal muscle. The deregulation
of Ca2+ homeostasis has since been confirmed by proteomics
in the diaphragm, skeletal muscle and heart [48].
However, to test a hypothesis one does not need to always
target the analysis, but can tailor the method for processing
the data. Gulston and co-workers [49] used the multivariate
regression technique prediction to latent structures by
partial least squares (PLS) to regress proteomic changes by
DIGE in order to investigate age-related changes in heart
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that the dominant proteomic changes associated with age
were the same in control and mdx mice. However, at each
time point the dystrophic heart tissue showed differences in
mitochondrial proteins, particularly those associated with
the electron transport chain and ATP synthesis.
With recent advances in MS, two-dimensional gel-based
proteomics has been faced with the problem of too many
proteins being detected in a dataset, with spots on the gel
often containing several proteins. To address this problem,
several groups involved in heart and skeletal muscle
proteomics have focused on organelle proteomics or tried
targeted approaches by looking at proteins that bind to a
given target.
M Me et ta ab bo ol lo om mi ic cs s   a an nd d   t th he e   m md dx x m mo ou us se e
Metabolic deficits or alterations have been reported in both
muscle - skeletal and heart - and brain tissue [40,50-54].
Furthermore, many of these changes are age specific and
will vary across the lifespan of the mouse. Although these
studies often confined themselves to one tissue and a small
subset of metabolites, in many cases these could be
considered the front-runner studies to a metabolomics
study of the mdx mouse.
One particularly elegant set of studies was performed by
McIntosh and co-workers [40,41], who established that
skeletal muscle taurine content correlated with the regenera-
tive capacity of muscle tissue in three mouse models: mdx,
MyoD (mutant in a protein with a key role in regulating
muscle differentiation) and mdx:MyoD cross mice, all at
4 months of age. Using in situ hybridization and auto-
radiography, the transcription of key genes involved in
muscle cell proliferation (myogenin and Myf5) were moni-
tored and compared with the tissue content of taurine, with
mdx tissue having the highest concentration of muscle
taurine as well as the greatest number of muscle proliferative
cells of the three mouse types.
Metabolic abnormalities have also been characterized in
cerebral tissue in sufferers of DMD and the mdx mouse
using chemical assays or 1H, 31P and 13C NMR spectroscopy
[55-57]. This reflects the fact that DMD sufferers experience
a non-progressive intellectual deficit. In both mdx mice and
DMD sufferers the cerebellum contains an increased con-
centration of choline-containing compounds, as measured
by the choline:N-acetyl aspartate ratio and the choline:creatine
ratio [57]. Curiously, the choline:N-acetyl aspartate ratio
correlated with improved neurological performance in DMD
boys, suggesting that it may be involved in a compensatory
mechanism.
Applying techniques developed for following drug toxicity
using a combination of 1H NMR spectroscopy and principal
components analysis [58], Griffin and co-workers [7]
examined a range of tissues from the mdx mouse, including
cardiac (Figure 1a), diaphragm, soleus (calf muscle), cerebral
cortex and cerebellum at 6 months of age. Dystrophic
muscle tissue from heart, diaphragm and soleus were
similarly perturbed metabolically by a failure to express
dystrophin, despite being very different types of muscle; this
was characterized by an increase in taurine and lactate and a
decrease in creatine in tissue extracts from dystrophic tissue.
This is in keeping with the single protein isoform known to
be involved in all these tissue types, and that presumably has
a similar role in all these tissues. These changes could be
detected even in intact tissue using high-resolution magic
angle spinning 1H NMR spectroscopy, which also identified a
significant increase in lipid infiltration in dystrophic tissue
[59]. Similarly, extracts of cerebellum tissue from mdx mice
were readily distinguished from wild-type controls by their
metabolic profiles, including a characteristic increase in
phosphocholine. The approach even found a weak separa-
tion in cortical tissue extracts, although this had not been
detected by previous studies. The changes in profiles of dys-
trophic muscle, cortex and cerebellum tissue were all
distinct, suggesting very different roles for the three iso-
forms of dystrophin in the tissues.
To investigate whether metabolic profiles could be used to
predict the proteomics of a disease or therapy regime, the 1H
NMR derived metabolic profiles of cardiac and diaphragm
tissue from four different mouse models with mutations in
the dystrophin or utrophin genes were examined [60].
Utrophin is functionally related to dystrophin, and its up-
regulation in skeletal muscle has been considered as a gene
therapy approach for treating DMD. During fetal develop-
ment, utrophin is found over the entire surface of muscle
fibers, but is replaced by dystrophin during development,
and utrophin becomes localized to the neuromuscular
junction in adult skeletal muscle [61-63]. The dystrophic
phenotype normally observed in mdx mice is absent when
muscles overexpress utrophin [64,65]. Furthermore, utro-
phin has a particularly favorable characteristic in dystrophic
tissue; although the body can treat dystrophin as a foreign
protein, mounting an immune response; increasing the
innate expression of utrophin does not have this pitfall [66].
In this metabolomic study [60], the PLS technique was used
to regress the metabolic profiles of tissue extracts against the
relative protein content of dystrophin and utrophin in four
mouse strains: (i) the mdx mouse, which does not express
dystrophin; (ii) Tgfull-length/Dmdmdx, a transgenic mouse
expressing full-length utrophin in skeletal muscle but not
heart crossed with the mdx mouse to produce mice lacking
dystrophin but with utrophin localized at the sarcolemma
[67]; (iii) Tg/Dmdmdx;utrn-/-, a transgenic mouse expressing
a truncated utrophin transgene crossed onto a Dmdmdx/utrn-/-
double mutant background, resulting in a mouse with no
dystrophin in skeletal muscle but with a truncated utrophin
http://genomemedicine.com/content/1/3/32 Genome Medicine 2009, Volume 1, Issue 3, Article 32 Griffin and Des Rosiers 32.4
Genome Medicine 2009, 1 1: :32transgene and heart with no dystrophin or utrophin [68];
and (iv) the control mouse to (iii), Tgtruncated/Dmdmdx, which
has no dystrophin but expresses utrophin. The PLS models
readily classified tissue according to dystrophin content for
the heart and diaphragm [60]. Examining the diaphragm,
models were built that described both dystrophin and utro-
phin expression. Furthermore, increased utrophin expres-
sion in dystrophic diaphragm tissue produced a metabolic
phenotype between that of the wild-type tissue and that of
the dystrophic tissue, suggesting that increased utrophin
expression counteracts some of the deficits associated with
dystrophic tissue. The major metabolite responsible for
classification of tissue into controls and dystrophic was
taurine, in keeping with it being a potential marker of
muscle regenerative capability. This suggests that metabolic
profiles of muscle tissue could be useful in monitoring the
efficacy of potential treatment regimes, such as gene therapy.
Cole and colleagues [69] have also examined the impact that
protein expression of utrophin and dystrophin has on
muscle metabolism, using 1H and 31P NMR spectroscopy to
examine ATP turnover in mdx mice, utrophin and dys-
trophin knockout mice and controls. In particular, the hind-
limb muscle in the double knockouts had reduced con-
centrations of ATP and creatine and increased intracellular
phosphate and ADP. Indeed, ADP could distinguish all three
mouse models examined.
Whereas it is clear that metabolomics and related approaches
can readily distinguish dystrophic tissue from that obtained
from wild-type controls for skeletal muscle, heart and brain
tissues, a word of caution is necessary when considering how
these results relate to human sufferers. One must remember
that the mdx mouse is relatively healthy in comparison with
human sufferers of DMD. Jones et al. [70] used high-
resolution 1H NMR spectroscopy to investigate the metabo-
lome of heart tissue from the mdx mouse, two mouse models
of cardiac arrhythmia and one of cardiac hypertrophy
(Figure 1b). Surprisingly, the dominant effect was the strain
background of the mice rather than the diseases they
modeled, suggesting that mouse models may have very
different phenotypes depending on the strain background on
which they are generated. However, multivariate statistics
were capable of separating each mouse model from its
control strain, showing that metabolic profiles could be
generated for each disease.
So far, the steady state concentrations of metabolites in
heart tissue have mainly been assessed by NMR spectros-
copy. However, because of the small population differences
associated with NMR spectroscopy, only a relatively small
number of metabolites can be detected. To expand the
metabolome, Atherton and colleagues [71,72] have used a
combination of NMR spectroscopy and gas chromatography
mass spectrometry (GC-MS) to detect over a hundred
aqueous metabolites and fatty acids. This has expanded the
coverage of the metabolome to over 250 individual species,
an order of magnitude more than those measured in the mdx
mouse. Han and co-workers [73] have used shotgun (direct
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F Fi ig gu ur re e   1 1
Applications of metabolomics and proteomics to the mdx mouse. ( (a a) ) A
typical high-resolution 1H NMR spectrum from an aqueous extract of
cardiac tissue from the mdx mouse. The chemical shift and splitting
pattern of a given resonance (peak) enables the identification of the
metabolite it belongs to, and the area under the resonance determines
the concentration of that metabolite. ( (b b) ) An orthogonal signal corrected
partial least squares discriminate analysis plot of various mouse models of
cardiac disease using solution state NMR spectroscopy. Key: circles,
control + mdx; diamonds, model of cardiac hypertrophy (MLPKO);
squares, model of cardiac arrhythmia (Scn-/+); triangles, model of cardiac
arrhythmia (Scn∆/+). ( (c c) ) Correlation analysis between identified proteins in
a proteomic study of heart tissue from mdx mice and the intracellular
concentration of taurine. When detected by 1H NMR spectroscopy
(bottom graph), taurine can be identified by two triple peaks at δ 3.25-
3.27 and δ 3.42-3.46. The correlation heat map between spectral intensity
and protein expression was used to determine which proteomic changes
were associated with the increase in taurine in dystrophic muscle. The x
axis is the chemical shift region containing the resonances from taurine;
the y axis consists of protein spots detected in the two-dimensional gel
electrophoresis. The color scale displays the correlation coefficients
between the two sets of data (concentration of taurine against
concentration of protein).
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PLS-DA 5infusion) MS to show that cardiolipin depletion in the
diabetic myocardium is a potential cause of mitochondrial
dysfunction. Expanding the shotgun approach to negatively
charged water-soluble metabolites using matrix-assisted
laser desorption ionization tandem time of flight MS
(MALDI-TOF/TOF MS), the group [74] have profiled over
285 chromatographic peaks in heart tissue. These studies all
indicate that metabolomic studies of the mdx mouse have
only scratched the surface of the metabolome.
F Fl lu ux xo om mi ic cs s   a an nd d   t th he e   m md dx x m mo ou us se e
The recent application of metabolic flux analysis to the mdx
mouse heart has provided an unexpected insight into the
metabotype [54,75]. Khairallah et al. [54] compared control
C57BL/10 and dystrophin-deficient mdx hearts from mice at
an age (10-12 weeks) during which there are no major
histological or echocardiographic abnormalities or differ-
ences in metabolic gene expression or metabolite concen-
trations as revealed by metabolomics [49]. This was achieved
using ex vivo heart perfusion in the working mode combined
with a 13C labeling methodology involving mass isotopomer
analysis by GC-MS. Principles and theoretical ideas relevant
to the use of 13C-isotopomer analysis as applied to cardiac
metabolism and methodological details on the working heart
perfusion model have been described in detail [15,54,76].
This experimental paradigm enables detailed and simul-
taneous determinations of various hemodynamic and
metabolic flux parameters relevant to energy production.
In the heart studies described by Khairallah et al. [54] four
different substrates uniformly labeled with carbon 13 (U-13C)
were used to probe metabolism in the mdx heart: the long-
chain fatty acid (LCFA) [U-13C18]oleate and the carbo-
hydrates (CHO) [U-13C3]lactate, [U-13C3]pyruvate and [U-
13C6]glucose. Metabolic flux ratios that were assessed
revealed cytosolic glycolysis, substrate selection (CHO
versus LCFA) for mitochondrial acetyl-CoA formation for
citrate synthesis (energy production), and pyruvate par-
titioning between decarboxylation (oxidation by pyruvate
dehydrogenase) and carboxylation (by pyruvate carboxy-
lase); see Figure 2. It is noteworthy that pyruvate carboxy-
lation participates in the refueling of catalytic Krebs cycle
intermediates, that is, in anaplerosis, a process that is
proposed to have a crucial role in optimal cardiac energy
production [77].
Compared with controls, working mdx mouse hearts had an
altered mitochondrial energy substrate metabolism, as
reflected by a marked shift from LCFA to CHO oxidation for
energy production; decreased anaplerotic pyruvate carboxy-
lation; and enhanced glycolysis [54]. These changes were
associated with exacerbated oxygen consumption and with
compromised function and integrity of the sarcolemma, as
reflected by lactate dehydrogenase release. Subsequent
targeted metabolite and protein analyses also revealed a
marked decrease in the myocardial mitochondrial Krebs
cycle pool size and lower activity of the Krebs cycle enzyme
aconitase, which further substantiate the presence of mito-
chondrial metabolic alterations in the heart of young mdx
mice. Although a substrate shift from LCFA to CHO, which is
a characteristic of several models of cardiomyopathies, could
be beneficial for the heart (for recent reviews see [78,79]),
the decreased levels of Krebs cycle intermediates and
decreased aconitase activity would be expected to limit the
ability of the dystrophic heart to enhance Krebs cycle flux
and thus limit mitochondrial energy production under
conditions of high energy demand.
A shift from LCFA to CHO oxidation in the dystrophic mdx
mouse heart agrees with results from cardiac positron
emission tomography studies in patients with DMD, using
18F-deoxyglucose or a radioiodinated branched fatty acid
([123I]15-(p-iodophenyl)-3-(R,S)-methylpentadecanoic acid
(BMIPP)) [80,81]. However, the aforementioned substantial
differences in the concentrations of Krebs cycle inter-
mediates between control and mdx groups documented in ex
vivo hearts perfused in the working mode contrasted with
the small changes documented in these hearts freeze-
clamped  in vivo [54], which also agreed with recent
metabolomic data [49]. This discrepancy between results
obtained ex vivo and in vivo suggest that despite providing
what are generally accepted to be physiological levels of
workload, nutrients and calcium supply, the ex vivo perfusion
environment unmasked major abnormalities of mdx cardiac
function and energy metabolism thereby exacerbating the
observed changes. Because these abnormalities are not
readily detected in vivo at this stage of the disease in the mdx
mouse, one would presume that homeostatic compensatory
mechanisms in the intact animal obscure these changes.
Numerous candidate mechanisms have been considered to
explain the documented metabolic flux alterations in
perfused dystrophin-deficient hearts at such an early
compensatory phase of the cardiomyopathy before heart
failure. These include the activity of cell signaling pathways
and changes in metabolic gene expression. Ultimately,
defective NO/cGMP signaling was hypothesized, as it
seemed to reconcile all data. Subsequent testing for this
cGMP signaling defect using transgenic and pharmacological
approaches showed improvement in contractile perfor-
mance, myocardial metabolic status and sarcolemmal
integrity, thus suggesting a potential clinical avenue for the
treatment of the dystrophin-related cardiomyopathies [75].
In summary, results obtained using the ex vivo working mdx
mouse perfused with 13C-labeled substrates together show
how changes in myocardial metabolic fluxes may be a
subclinical signature of defective cell signaling that occurs
before overt cardiomyopathy as well as providing a basis for
therapeutic strategies. The concomitant documentation of
pathophysiological changes (impaired contractile function
http://genomemedicine.com/content/1/3/32 Genome Medicine 2009, Volume 1, Issue 3, Article 32 Griffin and Des Rosiers 32.6
Genome Medicine 2009, 1 1: :32and membrane integrity) highlights the power inherent in
measuring metabolic fluxes as one part of predicting the
physiological phenotype of any organism. These data also
suggest a crucial role for myocardial dystrophin in main-
taining optimal coupling between energy metabolism and
contraction. Although the described 13C-labeling paradigm
focused on the measurements of carbon flow through the
Krebs cycle and related energy-producing pathways in the
heart, additional flux parameters could have been easily
assessed by extending the number of metabolites that were
analyzed by GC-MS. For example, in another study,
Khairallah et al. [82] also evaluated the 13C-enrichment and
concentration of LCFA in triglycerides to assess flux
pertaining to lipid partitioning between mitochondrial β-
oxidation (for energy) and triglyceride synthesis (for
storage), a process that can be used to monitor the toxic
effects of lipids, referred to as lipotoxicity.
Although the number of molecules analyzed can be increased
by using a combination of MS and NMR techniques [15,83],
the choice of 13C-labeled substrates can also determine the
number of metabolic flux parameters that can be extra-
polated in a given single experiment. In this regard, recent
studies demonstrated the potential of other 13C-labeled
substrates (for example [1,2-13C]glucose, [U-13C]glutamine
and deuterated water) [12,83-90].
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F Fi ig gu ur re e   2 2
Metabolic flux ratios assessed in working control (C) and mdx mouse heart perfused with 13C-labeled substrates. Data are given as means ± standard
errors (indicated in parentheses); n = 4-8 in each group. Reactions are shown in the part of the cell in which they take place. ( (a a) ) Flux ratios. (i) Flux ratios
reflecting the contribution of exogenous fatty acids (oleate) and carbohydrates (CHOs: lactate, pyruvate and glucose) to acetyl-CoA formation (energy)
and oxaloacetate (OAA; anaplerosis) via oleate β-oxidation (OLE), pyruvate decarboxylation (PDC) and carboxyation (PC), respectively, and expressed
relative to citrate synthesis (CS). (ii) Flux ratios reflecting the contribution of individual CHOs - as indicated by the individual arrows - to pyruvate
formation, expressed in percentage of total. ( (b b) ) Glycolytic rate, which reflects the production of lactate and pyruvate, in µmol x min-1. ( (c c) ) Tissue
concentration of Krebs cycle intermediates, in µmol x g wet weight-1. ( (d d) ) Tissue aconitase activity, in µmol x min-1 x mg protein-1. *p < 0.05, #p < 0.001
for mdx versus control mouse hearts. Adapted from Khairallah et al. [54].
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4.2 (0.3)*However, the use of isolated intact organs or cells can also
unmask abnormalities that are not readily observed in vivo
because of the existence of compensatory mechanisms in the
intact organism, as was the case for the isolated mdx heart
study [54,75]. Finally, there are several pitfalls to be wary of
in the application of metabolic flux analyses, including
corrections for natural stable isotope abundance and the
presence of overlapping fragments, which affect the accuracy
and precision of MS-based analyses [15,16,77,91-95]. There
are also limitations associated with the assumptions on
which the equations that form the metabolic models from
which flux ratios are calculated [96-98].
C Co on nc cl lu us si io on ns s: :   t to ow wa ar rd ds s   s sy ys st te em ms s   b bi io ol lo og gy y
Technological advances are improving the number of
proteins and metabolites that can be measured by com-
bining NMR- and MS-based technologies. Recent studies
clearly show the added value of dynamic metabolomics or
fluxomics as applied to the discovery of metabolic pathways
related to hepatic gluconeogenesis [87,88] or to the probing
of drug therapy in cultured cells [84-86]. However, although
metabolomics and proteomics are approaches that lend
themselves to functional genomic analyses, the accurate and
precise determination of metabolite fluxes is substantially
more time consuming and cannot be readily adapted for
functional genomic analyses. Furthermore, even with im-
provements in analytical technology, one problem common
to proteomics, metabolomics and fluxomics is the in-
complete coverage of the tiers of organization. Proteomics
and metabolomics detect only a small subset of the total
proteome and metabolome, and fluxomics tends to focus on
discrete pathways determined in part by the substrates that
are used for the analysis. One method to remedy this is to
combine the analysis of different ‘-omes’. Although, so far,
there are only few examples of such studies [49,99-102], this
is likely to be a rapidly expanding field. We have illustrated
the potential added value of combining information from
proteomics, metabolomics and fluxomics as applied to the
mdx mouse. Indeed, the combined metabolomics and
proteomics (by DIGE) approach used by Gulston and co-
workers [49] enabled the demonstration of a correlation
between the characteristic increase in taurine found in the
heart and skeletal muscle of these mice and proteins
associated with oxidative phosphorylation and mitochon-
drial metabolism (Figure 1c). Conversely, flux studies in the
working mdx mouse heart further substantiated the specific
mitochondrial alterations related to energy substrate
metabolism in the Krebs cycle [54], which were not apparent
in histology or echocardiograms, or detected by trans-
criptomics or metabolomics at this age [49] and provided
the basis for a successful therapeutic intervention [75].
Collectively, these data point to perturbations in proteins,
metabolites and metabolic fluxes that reflect mitochondrial
energetic alterations in skeletal and heart muscles at an early
stage of the dystrophic pathology.
In conclusion, we have examined how recent advances in
proteomics, metabolomics and fluxomics have been used to
study various aspects of a pathophysiology, as applied to
muscular dystrophy. These approaches have produced new
insights not only into the disease process, which provides a
basis for therapeutic strategies or for biomarker screening,
but also into the basic biology of the cell. Such studies will
take the field from a genomic description towards a fuller
understanding of the systems biology of the disease.
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